-
Lymphoma Cancer Associated With Breast Implants: FDA Advisory Committee Meeting March 2019
Warning Letters Sent To Companies Mentor Worldwide And Sientra For Breast Implants Safety Monitoring Failures (Posted by Tom Lamb at DrugInjuryWatch.com) Albeit a bit off-topic for the general focus of this Drug…
-
Gadolinium Contrast Agents Side Effects: Medical Literature Review, September 2018 – February 2019
Researchers Continue To Investigate Gadolinium Deposition Disease (GDD) Following Gadolinium-Based Contrast Agents Injections (Posted by Tom Lamb at DrugInjuryWatch.com) In recent years it has been recognized that the gadolinium contained in certain…
-
Xeljanz Recommended Dosage For Ulcerative Colitis Patients May Increase Risk Of Pulmonary Embolism
FDA Is Reviewing Safety Of Xeljanz 10 mg Twice-Daily Dose Of This JAK Inhibitor, According to February 2019 News Reports (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: FDA Drug Safety Communication: "Safety…
-
Breast Implants Lymphoma Cancer Cases Updates For United States And Canada: February 2019
Additional Cases Of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Reported To FDA, Health Canada (Posted by Tom Lamb at DrugInjuryWatch.com) For our first 2019 update about breast implant-associated anaplastic large cell…
-
Januvia, Onglyza, Other Diabetes Drugs In DPP-4 Inhibitor Class Significantly Increase Risk Of Crohn’s Disease (CD)
But Same Medical Study Finds That DPP-4 Inhibitors Do Not Increase Risk Of Inflammatory Bowel Disease (IBD) (Posted by Tom Lamb at DrugInjuryWatch.com) Back in March 2018 we wrote this report, “Januvia,…
